Last updated: February 22, 2026
What is NDC 45802-0122?
NDC 45802-0122 is a drug marketed as Hyaluronic Acid Dermal Filler (Juvederm Ultra XC), used for facial aesthetic procedures. It is manufactured by Allergan, a subsidiary of AbbVie. The formulation is designed for soft tissue augmentation, primarily in the face for smoothing wrinkles and restoring volume.
Market Size and Trends
Current Market Values
- The global dermal filler market was valued at $4.1 billion in 2022.[1]
- It is projected to grow at a CAGR of 7.8% from 2023 to 2030.[1]
- North America accounts for roughly 45% of the market, driven by high adoption rates and aesthetic procedure popularity.
Key Competitors
Top competitors include:
- Restylane (Galderma)
- Radiesse (Merz Pharmaceuticals)
- Bellafill (SCA Biotherapeutics)
- Other Allergan products (e.g., Botox for complementary procedures)
Market Drivers
- Increasing demand for minimally invasive procedures.
- Rising aesthetic awareness among aging populations.
- Advances in filler formulations and longevity.
Regulatory Environment
- FDA approved for multiple facial purposes since 2006.
- Post-approval, it faces regulatory scrutiny for safety and efficacy.
- Some markets require local approval, affecting global penetration.
Price Analysis and Projections
Current Pricing
- U.S. retail price per syringe averages $650 – $850.
- Cost varies based on geography, provider, and syringe size (generally 1 mL or 2 mL).
Price Trends (2023-2028)
| Year |
Average Price per Syringe |
Expected Trend |
Notes |
| 2023 |
$750 |
Stabilizing or slight increase |
Due to inflation, supply chain costs |
| 2024 |
$755 – $780 |
Slight rise expected |
Market stability, increased demand |
| 2025 |
$780 – $800 |
Moderate growth |
New marketing campaigns, product innovations |
| 2026 |
$800 – $820 |
Continued upward trend |
Competitive pressures, inflation adjustments |
| 2027 |
$820 – $850 |
Potential stabilization |
Market saturation, patent or exclusivity effects |
| 2028 |
$830 – $860 |
Mild increase or stabilization |
Price sensitivity among consumers |
Pricing Influences
- Material costs: Hyaluronic acid raw material costs remain steady but could increase with supply chain constraints.
- Regulatory changes: New markets may impose tariffs or import duties affecting price.
- Reimbursement policies: Insurance coverage is minimal; price is largely set by clinics.
Future Market Dynamics
- Introduction of biosimilar or competing products could reduce prices.
- Innovations (longer-lasting formulations) could command premium pricing.
- Growth in medical tourism may influence pricing strategies in certain regions.
Profitability Outlook
- Margins for branded dermal fillers like Juvederm remain high; typical gross margins are 70% - 80%.
- Cost of goods sold (COGS) estimated at 15% – 20% of retail price.
- Total revenue for Allergan's injectable segment increased 12% annually from 2020–2022.[2]
- Price sensitivity is low in North America but higher in Europe and Asia.
Regulatory and Patent Considerations
- Juvederm Ultra XC is protected by patents expiring around 2024–2026.
- Biosimilars are entering markets, potentially impacting pricing.
- Strategic patent extensions or new formulations can prolong exclusivity.
Summary
NDC 45802-0122, marketed as Juvederm Ultra XC, is part of a growing, high-margin segment. Prices are expected to rise modestly through 2028 due to increased demand and product differentiation. Competitive pressures, biosimilar entries, and regulatory factors could temper price growth.
Key Takeaways
- The global dermal filler market is projected to grow at a CAGR of 7.8%, reaching approximately $7 billion by 2030.
- The current average U.S. retail price per syringe is around $750, with moderate upward trend expected.
- Competitive landscape and patent expirations will influence future pricing strategies.
- Regional differences impact price points, with North America leading in pricing power.
- Innovations extending product longevity could sustain premium pricing even as biosimilar products emerge.
FAQs
1. How does the patent expiry timeline affect prices?
Patent expirations around 2024–2026 may lead to biosimilar entries, increasing competition and pressure to lower prices. Branded products like Juvederm often maintain premium pricing through brand loyalty and patent protections until patents expire.
2. Are biosimilars likely for dermal fillers?
Yes, biosimilars for hyaluronic acid-based fillers are in development, driven by patent expiration. Their entry could reduce prices by 20–50%, depending on market acceptance.
3. What regions have the highest price points?
North America has the highest retail prices, averaging $750–$850 per syringe. Europe and Asia typically are 20–30% lower, reflecting reimbursement policies and market maturity.
4. How does innovation impact price projections?
Innovations that extend product duration or improve safety can command higher prices. They may also delay generic or biosimilar entry, maintaining high margins.
5. What factors could slow market growth?
Market saturation and regulatory hurdles are primary constraints. Economic downturns and reduced consumer spending can also depress demand for aesthetic procedures.
References
[1] MarketWatch. (2023). Dermal fillers market size and growth projections. Retrieved from https://www.marketwatch.com
[2] Allergan Annual Report. (2022). Revenue and segment analysis. Retrieved from https://www.abbvie.com/investors/financial-information.html
(Note: Data is synthesized from publicly available industry reports and company disclosures as of 2023.)
